ArticleAmerican journal of cancer research2016
Volasertib suppresses the growth of human hepatocellular carcinoma
Article in American journal of cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- PLK1: A Promising Therapeutic Target for Prostate Cancer Treatment.Serican journal of medicine · 2024Article
- Reduction-responsive nucleic acid nanocarrier-mediated miR-22 inhibition of PI3K/AKT pathway for the treatment of patient-derived tumor xenograft osteosarcoma.Bioactive materials · 2023Article
- Characterization of diagnostic and prognostic significance of cell cycle-linked genes in hepatocellular carcinoma.Translational cancer research · 2021Article
- Fenretinide induces a new form of dynamin-dependent cell death in pediatric sarcoma.Cell death and differentiation · 2020Article
- Volasertib preclinical activity in high-risk hepatoblastoma.Oncotarget · 2019Article
- Targeting TF-AKT/ERK-EGFR Pathway Suppresses the Growth of Hepatocellular Carcinoma.Frontiers in oncology · 2019Article
- Celastrol Inhibits the Growth of Ovarian Cancer CellsFrontiers in oncology · 2019Article
- Survivin Promotes Piperlongumine Resistance in Ovarian Cancer.Frontiers in oncology · 2019Article
- Erastin Reverses ABCB1-Mediated Docetaxel Resistance in Ovarian Cancer.Frontiers in oncology · 2019Article
- Survival analysis of genome-wide profiles coupled with Connectivity Map database mining to identify potential therapeutic targets for cholangiocarcinoma.Oncology reports · 2018Article
- Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.Oncotarget · 2018Article
- YM155 enhances docetaxel efficacy in ovarian cancer.American journal of translational research · 2018Article
- Cyclin-dependent kinase 7 inhibitor THZ2 inhibits the growth of human gastric cancerAmerican journal of translational research · 2018Article
- Volasertib Enhances Sensitivity to TRAIL in Renal Carcinoma Caki Cells through Downregulation of c-FLIP Expression.International journal of molecular sciences · 2017Article
- Article
Corrections and comments
- Retraction · 2020-05-01Falsification/Fabrication of Data ·
- Retracted
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the sixth most frequent malignant tumor with poor prognosis, and its clinical therapeutic outcome is poor. Volasertib, a potent small molecular inhibitor of polo-like kinase 1 (PLK1), is currently tested for treatment of multiple cancers in the clinical trials. However, the antitumor effect of volasertib on HCC is still unknown. In this study, our data show that volasertib is able to induce cell growth inhibition, cell cycle arrest at G2/M phase and apoptosis with the spindle abnormalities in human HCC cells. Furthermore, volasertib also increases the intracellular reactive oxidative species (ROS) levels, and pretreated with ROS scavenger N-acety-L-cysteine partly reverses volasertib-induced apoptosis. Moreover, volasertib markedly inhibits the subcutaneous xenograft growth of HCC in nude mice. Overall, our study provides new therapeutic potential of volasertib on hepatocellular carcinoma.
Indexed as
Identifiers
27904765PMC5126267W2559888071What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.